HIV Drug Access Increase Under Licensing Deal

US pharmaceutical giant Gilead Sciences and an NGO called the Medicines Patent Pool announced a deal on Tuesday aimed at boosting access to HIV drugs in poorer countries through generic manufacturing.

The HIV medicines tenofovir and emtricitabine, as well as two drugs that are still in clinical development, cobicistat and elvitegravir, will be made in low-cost copycat form under the licensing agreement.

Ranbaxy Subsidiary in Rs 605 Crore Deal to Supply Anti-HIV Drugs in SA
Ranbaxy Laboratories has announced that its South African joint venture, Sonke Pharmaceuticals has bagged a deal worth Rs 605 crore to supply anti-HIV drugs

Included too is a combination of these drugs in a hoped-for single pill known as the Quad.

The Medicines Patent Pool, founded by AIDS campaign group UNITAID in 2010, seeks to widen access to HIV drugs through voluntary licences with Big Pharma.

The new deal is unusual because pharmaceutical companies very rarely allow licensing of drugs for public health while the product is still in clinical development.

HIV Drugs Need To Break Into Brain Sanctuary
HIV drugs need to break into the brain sanctuary to become more effective than they are now, say Dr Lachlan Gray and his colleagues at Monash University and the Burnet Institute.

"Today marks a milestone in managing patents for public health. The licence agreement with Gilead Sciences will help make medicines available at a lower cost and in easier-to-use formulations without delays," said Ellen 't Hoen, executive director of the Medicines Patent Pool.

"(...) People in developing countries often have to wait for years before they can access new health technologies. Today's agreement changed that."

Some HIV Drugs Cause Premature Aging
Some anti-retroviral drugs used to treat HIV infections cause premature aging, according to a recently published research work.

Gilead will pick up royalties of three to five percent of generic sales, but will waive royalties for any formulations of the drug that are used for children.

Generic drugs have been essential in the effort to cast a lifeline to the millions of people in poor countries who are badly infected by the human immunodeficiency virus (HIV).

HIV Drugs May Target Malarial Parasites in the Future
Scientists have discovered that drugs used to treat HIV may also one day become lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria.

Thanks to generics, the cost of the least expensive first-generation HIV treatment has dropped to less than $86 a patient annually from $10,000 in 2000.

However, doctors need alternatives to these front-line drugs because some patients fail to respond to the treatment. In addition, the AIDS virus mutates, posing a long-term resistance problem.

It is the first agreement between the Medicine Patents Pool and a pharmaceutical company.

UNITAID, headed by former French foreign minister Philippe Douste-Blazy, was set up in September 2006 to boost funding to fight AIDS, tuberculosis and malaria. Its funding derives from a solidarity levy on airline tickets sold in 15 countries.

Source-AFP